Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Atea Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenax Therapeutics (TENX – Research Report) and Atea...

Market Cap	$258.71M	P/E Ratio	N/A
52W High	$4.02	52W Low	$2.46
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-49.9%	52W Position	32.9%
Overall Score	52	Value Score	60
Quality Score	--	Technical Score	45

EPS Current Est	$-1.73	EPS Next Est	$-1.75
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AVIR	$2.97	-1.00%	568.12K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AVIR	$2.97	-1.0%	568.12K
3
4
5
6

AVIR

AVIR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Atea Pharmaceuticals Inc. Data in Excel

Get Atea Pharmaceuticals Inc. Data in Excel